A gene can be perfectly understood and still be awkward to deliver. Consider ABCA4, whose mutations cause Stargardt disease. Its instructions are too large for conventional gene replacement using a single adeno-associated virus, or AAV. The familiar vehicle is small; the cargo refuses to fold. Ascidian Therapeutics built its first clinical program around that inconvenience.
- The idea: replace faulty RNA exons using the cell’s own splicing machinery.
- The first test: ACDN-01, an investigational treatment for ABCA4-related retinal disease.
- The business: develop the retinal candidate internally; license selected targets to Roche and Lilly.
- The hurdle: establish lasting patient benefit, beyond an ingenious molecular design.
A manuscript with replaceable passages
DNA supplies the instructions. RNA carries a working version toward protein production. Before that message is ready, the cell removes intervening sequences and joins the useful passages, called exons. Ascidian inserts a designed RNA molecule into this editing process. Through pre-mRNA trans-splicing, separate RNA molecules are joined, replacing mutated exons with healthy versions.
The attraction is scale. A base editor corrects individual letters; an exon editor can replace whole passages containing different mutations in different patients. That could allow one construct to cover numerous disease-causing variants. The company also aims to preserve the cell’s native patterns of gene expression. Correct protein matters, but so do its quantity, location and timing.
Conceptual illustration of the platform’s intended mechanism, not a measure of clinical efficacy.
Its name comes from ascidians, better known as sea squirts, which use trans-splicing in their own biology. An unglamorous ocean creature is a fine corrective to biotechnology’s taste for grand names. Nature had already supplied the mechanism. Turning it into a medicine required a different collection of tools.
The old idea that needed new instruments
Therapeutic trans-splicing has a history before Ascidian. A 2024 scientific review by its researchers describes earlier attempts limited by low efficiency or weak translation into preclinical models. The obstacle was making the reaction happen reliably enough to matter.
Ascidian combines high-throughput molecular biology, computational design and deep sequencing to identify and assess editors. Better measurement helps researchers detect both the intended products and unwanted reactions. The underlying lesson is practical: a biological trick becomes more useful when it can be screened, counted and challenged.
ATP created and incubated the company, with Michael Ehlers as founding CEO. Its public launch in October 2022 came with $50 million in Series A financing and Romesh Subramanian as president and CEO. In November 2023, ATP committed another $40 million; Ehlers returned to lead the business. Scientific development had acquired a substantial financial runway.
Ten adults, then a younger question
ACDN-01 uses a single AAV vector to deliver the RNA exon-editing construct. The target is ABCA4-related retinopathy, including Stargardt disease, an inherited condition that damages central vision. A defective ABCA4 protein allows harmful waste material to accumulate in the retina. The candidate is designed to restore production of functional, full-length protein.
On May 4, 2026, Ascidian announced completion of adult dose escalation in its Phase 1/2 STELLAR trial. Ten participants, aged 18 to 77, had enrolled in that portion. The company expanded enrollment to pediatric participants aged 12 and older and presented first-in-human safety data at ASGCT that month.
Completed dose-escalation enrollment.
Early clinical development, not proof of a cure.
The distinction matters. STELLAR evaluates safety and preliminary efficacy following one subretinal injection. A successful procedure or completed cohort does not establish durable preservation of sight. The proposed convenience of one administration must earn its value through follow-up.
Patients encounter Ascidian through research participation. STARPATH, its observational prescreening study for adults and children aged five and older, provides genetic testing and retinal imaging without a study drug. Eligibility for treatment depends on the mutations involved and other study criteria. Prescreening offers information, not a guaranteed place in a treatment trial.
Two partners buy specific doors
The company’s commercial counterparties are pharmaceutical developers. Roche’s June 2024 agreement provided a $42 million initial payment for exclusive rights tied to undisclosed neurological targets. Ascidian could also receive up to $1.8 billion in milestones, plus royalties. Roche takes responsibility for later clinical development, manufacturing and commercialization.
Lilly followed in June 2026 with a collaboration for undisclosed inherited kidney-disease targets. Ascidian leads discovery and selected preclinical work; Lilly handles additional preclinical activities and downstream development. The announced potential payments reach $1.9 billion, including an upfront payment and milestones, with tiered royalties on worldwide sales.
Those billion-dollar headlines are conditional economics. They describe future possibilities rather than an account balance. The useful contractual detail is narrower: both partnerships concern selected targets, leaving Ascidian room to pursue others. A founder can copy the negotiating principle of preserving future options, although the leverage required to secure such terms is earned.
The experiment must survive the factory
In January 2026, Ascidian announced a manufacturing partnership with Forge Biologics for ACDN-01, covering process and analytical development, toxicology and cGMP production. Manufacturing supplies the less picturesque half of the story: material that can be made consistently for clinical use.
There are competing designs. SpliceBio’s investigational SB-007 uses two AAV vectors and protein splicing to tackle Stargardt disease. Ascidian’s single-vector RNA approach offers a different answer to the cargo problem. The comparison establishes an engineering distinction; clinical evidence must settle the question of patient benefit.
Delivery, sufficient editing and appropriate mutation coverage remain conditions for the approach to work. Repairing instructions also cannot be assumed to replace retinal tissue already lost. In July 2026, Ehlers moved to board chair and Daniel Rosan became president during a CEO succession process. The manuscript has an editor. The trial still has to show what the revision achieves.
“Our focus now is on execution”
Daniel Rosan / July 2026